Company launches clinical study of AI-designed oral formulation following MHRA approval, marking a major milestone in AI-driven drug development.
The newly licensed platform enables precise control over both the drug-to-antibody ratio and payload attachment sites in single- and dual-payload ADCs
The company is set to unveil new clinical data across obesity, diabetes, kidney, and liver disease programs
The approval has been secured in partnership with Yabao Pharmaceuticals, a major player in China’s paediatric medicine segment
BMS is moving beyond conversational AI into what it describes as “agentic” systems
Doshi has established a strong track record in driving quality assurance, regulatory compliance, and formulation excellence across complex pharmaceutical operations
The platform combines internally developed technologies, strategic partnerships, and external AI capabilities
Funding to support clinical development, gene therapy pipeline expansion and GMP manufacturing capabilities
Shilpa will deliver end-to-end services including CMC development, process scale-up, GMP clinical supply, and commercial manufacturing support
We are building an AI-native operating system for pharma sales and distribution
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
